In a quiet year for takeouts, who was buying?
Small and mid-sized developers upped deal-making activity last year, a deep dive into M&A data finds.
Biopharma’s stock market winners of 2021 revealed
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
What Novartis could buy with its windfall
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Novartis pushes on with iscalimab after transplant disappointment
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
Fortunes diverge for solo drug launchers
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Quiet times return for biopharma takeouts
The first quarter of 2021 saw fewer deals than any in recent memory.
A busy year ahead for Parkinson’s disease
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
Horizon pays $3bn to bolster its pipeline
But forecasts of over $3bn in annual peak sales from Viela’s portfolio look steep.
Finding the next Vertex
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
